2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2287

Evaluation of the Fibromyalgia Rapid Screening Tool (FiRST) Questionnaire to Screen Fibromyalgia Associated with Inflammatory Rheumatic Disease
Abstract Number: 2651

Evaluation of the Impact of Disease-Modifying Antirheumatic Drugs on Anti-Cyclic Citrullinated Peptide Autoantibody Levels in Clinical Practice
Abstract Number: 670

Evaluation of the Predictive Value of Non-Specific Musculoskeletal Symptoms in Preclinical Phases of Psoriatic Arthritis
Abstract Number: 883

Evaluation of Thiopurine Metabolites Monitoring in Patients Treated with Azathioprine for Rheumatic Diseases
Abstract Number: 289

Evaluation of Usefulness of Krebs Von Den Lungen-6 As a Biomarker of Interstitial Lung Disease with Polymyositis and Dermatomyositis Including in the Short Time Course after Treatment
Abstract Number: 2082

Evaluations of Social Support Are Associated with Well-Being Outcomes in Women with Systemic Lupus Erythematosus (SLE)
Abstract Number: 194

Events Upstream of Caspase-1 Activation in NLRP3-Mediated Cell Death in NOMID
Abstract Number: 1617

Evidence for Citrullinated Inhibitor of DNA Binding 1 (Id1) As a Novel Autoantigen Candidate in Rheumatoid Arthritis
Abstract Number: 3123

Evidence of Altered Blood Brain Barrier Permeability in Systemic Lupus Erythematosus Using Magnetic Resonance Imaging
Abstract Number: 2838

Evidence of Serological IL-23/IL-17 Axis Activation in Ankylosing Spondylitis Patients with Long-Term TNF Blockade: The Missing Therapy Target?
Abstract Number: 2453

Evidence-Based Decision Support for Pediatric Rheumatology Reduces Diagnostic Errors, with the Potential to Reduce Capacity Shortage
Abstract Number: 2936

Evolution of Disease Burden over 7 Years in a Multicentre Inception SLE Cohort
Abstract Number: 2450

Examination of the Clinical Significance of 14-3-3 Eta in Juvenile Idiopathic Arthritis
Abstract Number: 3261

Examining the Impact of Radiation Therapy on Scleroderma and Cancer Outcomes in Scleroderma Patients with Breast Cancer
Abstract Number: 2973

Exercise Intolerance Evaluated By Invasive Cardiopulmonary Exercise Testing in Connective Tissue Disease: Beyond Pulmonary Hypertension

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].